Reporting Adverse Events for Cannabis to the FDA

To the Editor: We would like to clarify a statement in the letter by Mudan et al. (Sept. 12 issue) 1 suggesting the lack of a national pharmacovigilance database for reporting adverse events associated with products containing cannabis. Consumers and health care professionals can directly report to the FDA MedWatch program 2 adverse events and other problems, such as product quality issues or medication errors, that they believe are associated with medical products. Although the majority of reports received are for FDA-approved products, reports regarding unapproved products, including cannabis and cannabis-derived products, are accepted through this pathway. The FDA has received reports . . .